Who are Nicotine Replacement Therapy Agent - Patches's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nicotine (4 mg), Transdermal Nicoderm patch, Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge, nicotine patch, labeled use, Placebo Tablet and Nicotine Patch, Pre-Quit Nicotine Gum.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicotine-replacement-therapy-agent-patches.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Nicotine Replacement Therapy Agent - Patches — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nicotine Replacement Therapy Agent - Patches (Nicotine Replacement Therapy Agent - Patches) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy agent. Area: Addiction Medicine / Smoking Cessation.

phase 3 Nicotine replacement therapy agent Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule Live · refreshed every 30 min

Target snapshot

Nicotine Replacement Therapy Agent - Patches (Nicotine Replacement Therapy Agent - Patches) — NYU Langone Health. Nicotine patches deliver nicotine transdermally to bind nicotinic acetylcholine receptors in the brain, reducing withdrawal symptoms and cravings during smoking cessation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nicotine Replacement Therapy Agent - Patches TARGET	Nicotine Replacement Therapy Agent - Patches	NYU Langone Health	phase 3	Nicotine replacement therapy agent	Nicotinic acetylcholine receptors
Nicotine (4 mg)	Nicotine (4 mg)	GlaxoSmithKline	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Transdermal Nicoderm patch	Transdermal Nicoderm patch	Ottawa Heart Institute Research Corporation	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
nicotine patch, labeled use	nicotine patch, labeled use	University of Vermont	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy agent class)

NYU Langone Health · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nicotine Replacement Therapy Agent - Patches — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotine-replacement-therapy-agent-patches. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab